125 results on '"Iveson, Tim"'
Search Results
2. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
3. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts
4. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis
5. A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
6. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
7. Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
8. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
9. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis
10. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer
11. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
12. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
13. Adjuvant chemotherapy in colon cancer: state of the art and future perspectives
14. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets
15. Accounting for intensity variation in image analysis of large‐scale multiplexed clinical trial datasets.
16. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
17. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
18. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
19. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer
20. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
21. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
22. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
23. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
24. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
25. Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation
26. Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study
27. Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
28. Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study
29. Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
30. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer
31. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
32. FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
33. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
34. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
35. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
36. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer
37. Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
38. More Oncologists, Please
39. TAS 102 in refractory metastatic colorectal cancer: UK Expanded Access Programme experience.
40. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
41. Prognostic utility of the presence of extramural vascular invasion in stage II and III colorectal cancer: Data from the FACS randomised controlled trial.
42. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
43. Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.
44. Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.
45. Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.
46. Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
47. Outcome of second-line chemotherapy for biliary tract cancer
48. Quality of life, long-term survivors and long-term outcome from the ABC-02 study.
49. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
50. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.